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Short title: « Adsorption of antibacterial drugs in ECMO circuit » 
 
 
ABSTRACT 
 
Extracorporeal membrane oxygenation (ECMO) procedure used in the management of patients with 
cardiac and/or respiratory failure could modify drugs pharmacokinetics (PK) properties. Studying the 
impact of ECMO devices on drugs PK is warranted to optimize dosage and ensure clinical outcomes. 
We aimed to characterize the behavior of four cephalosporins and three carbapenems commonly 
used in an ECMO circuit with an in-vitro approach focusing on the coated tubing, support of the 
extracorporeal circulation. Results suggest that these antibiotics are not sequestrated by ECMO 
tubing. This pilot mechanistic study provides original data that will contribute to improve our 
understanding of the impact of ECMO on the PK of drugs commonly used in intensive care unit 
patients. 
 
Keywords: Extracorporeal membrane oxygenation; pharmacokinetics; adsorption; antibiotics; 
intensive care. 
 
Extracorporeal membrane oxygenation (ECMO) is a supportive care used in the management of 
patients with life-threatening cardiac and/or respiratory failure. The use of ECMO in the management 
of cardiopulmonary disease is increasing. Since its first application in the 70’s, performances of the 
technology and devices have been dramatically improved, leading to safer and more effective system 
(1). Hence, indications of ECMO have expanded, and are also becoming better defined, although 
data from clinical trials are needed in order to build thorough practice guidelines (1,2). In addition to 
clinical aspects, potential impact of ECMO on the pharmacokinetics (PK) of drugs used in these 
patients must be considered to improve the therapeutic strategy. The alterations in PK parameters 
described in the critically ill population eligible for ECMO therapy may induce additional PK variability 
(3). Although clinical data are sparse, recent studies suggested that ECMO circuit itself is responsible 
for PK alterations which could increase the risk of therapeutic failure or toxicity (3–7). Sequestration of 
drugs in ECMO circuits has been proposed as an explanation for the low concentrations observed in 
clinical practice (4,8). Thus, studies on the impact of ECMO devices on drug PK are warranted to 
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optimize dosage and ensure treatment efficacy. During antibacterial treatment, the early achievement 
of drugs concentrations within the therapeutic target is associated with improved outcome. More 
specifically, for betalactam agents, maintaining drug concentrations above the minimal inhibitory 
concentration of the drug on the bacteria targeted is crucial to ensure treatment success (9). Among 
the factors potentially associated with subtherapeutic levels of betalactam agents, ECMO is a major 
cause of concern, as this intervention applies to the sickest patients, for whom sub-optimal use of 
drugs will be life-threatening (10).  
 
We aimed to characterize the behavior of antibiotics (ATB) commonly used in these patients 
(betalactam agents), in an ECMO circuit with an in-vitro approach focusing on the coated tubing 
support of the extracorporeal circulation. 
 
Cephalosporins (CS: cefotaxime, ceftriaxone, ceftazidime, cefepime) and carbapenems (CP: 
imipenem, meropenem, ertapenem) were bought from local drug purchases companies and prepared 
following label instructions for clinical use in humans. Drug-free human whole blood obtained from the 
Etablissement Français du Sang (Rennes, France) was spiked with ATB to reach concentrations 
closed to the peak concentration of each drug. Blood samples were disposed in PVC Bioline® coated 
tubing (Maquet, Germany) from an ECMO device system (experimental conditions), or inert glass 
tubes (control conditions). Samples were incubated at 37°C under agitation to mimic real conditions. 
Plasma concentrations of the drugs were assessed just before and after 5, 15, 30, 60, 120 and 240 
minutes of incubation for experimental and control groups. This design aimed to detect a potential 
sequestration of drugs by the device. The whole experiments were replicated five times. 
Cephalosporin concentrations were measured using high performance liquid chromatography (HPLC) 
associated with UV-spectrometry detection and according to the validated method reported by Verdier 
et al. (11). The method used to quantify carbapenems was adapted from (12). Briefly, analytes were 
extracted from plasma using protein precipitation with acetonitrile followed by a liquid-liquid extraction 
with dichloromethane. Extracts were analyzed by HPLC tandem mass spectrometry. 
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Changes in mean remaining drug concentrations over time were compared between control and 
experimental conditions by modeling using a linear mixed effect model as previously done in some 
similar studies (5,13). The mixed effect model was then fitted with R software version 3.0.2 and the 
“nlme” library (14). 
No significant differences in remaining concentrations in tubing or controls were observed for CS and 
CP. This suggests that CS and CP are not sequestrated by ECMO tubing (Figure 1). After 4 hours of 
incubation at 37°C, the decrease in drug concentrations was significant (> 15%) for imipenem, 
cefepime and cefotaxime, but with the same extent in the controls and the experimental conditions, 
and thus can be ascribed to sub-optimal drug stability of most betalactam agents.  
These results show that PK changes in ECMO patients treated with CS or CP might not be due to 
tubing sequestration. It was suspected, on the ground that betalactam are hydrophilic drugs. Indeed, 
Wildschut et al., reported a correlation between octanol/water partition coefficient (log P) of a drug 
and its clearance during ex-vivo procedure conducted with neonatal circuits. These authors have 
showed that drug loss in ECMO circuit is lower for hydrophilic drugs such as betalactam (7). A lack of 
effect of ECMO on the PK of hydrophilic drugs has also been highlighted in patients, particularly with 
the antiviral oseltamivir (6). On the opposite, Shekar et al. have reported a substantially higher 
clearance of meropenem, a CP drug, during ex-vivo experiments and in adult patients treated with 
ECMO (4,10). In a larger case-control study, no difference was found in meropenem PK between 
ECMO patients and non-ECMO patients (15). In view of these conflicting results, experimental study 
like the present one appears useful to understand underlying mechanisms which make ECMO device 
a factor of PK modifications. Thus, PK alterations of hydrophilic drugs might be more likely due to 
hemodilution mechanism associated with the additional compartment represented by the circuit or 
high volume of fluid supplementation requested in intensive care patients. Nevertheless, log P value 
of a drug is not the only parameter determining the drug disposition in an ECMO circuit. Shekar et al. 
have demonstrated in an ex-vivo study that as lipophilicity, degree of protein binding may be involved 
as well (13). In the present work we did not observed any influence of this factor since drugs studied 
have disparate levels of protein binding (respectively 70%, 2%, 95%, 30%, 90%, 10%, 19% for 
imipenem, meropenem, ertapenem, cefotaxime, ceftriaxone, ceftazidime, cefepime) but the same 
profile of drug recovery in the circuit compared to the control group (no significant difference). 
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However, Other source of PK alteration during ECMO procedure could not be excluded. Drug 
adsorption on the circuit may also depend on circuit duration of use, since binding sites may become 
saturated after a few hours of operation (16). Besides, it would be worth to perform further 
experiments focusing on the other components of the system which may be involved in drug 
sequestration, in particular the membrane oxygenator. It is admitted that in-vitro studies have 
limitations and working with animal model could be considered. Such an approach has been 
proposed by Shekar et al. (17) but to date no results has been published. However, animal model 
request special environment and expertise making this kind of studies hard to implement. 
Thus, this pilot mechanistic study provides original data that will contribute to improve our 
understanding of the impact of ECMO on the PK of drugs commonly used intensive care patients. CS 
and CP drug sequestration on ECMO tubing seems unlikely but other causes of drug loss within 
circuit have not been ruled out. Complementary in-vitro, ex-vivo and patient studies should be 
planned to completely explore the PK of betalactam antibiotics during ECMO. This is the next step of 
a translational project ongoing in our center. It includes in-vitro data presented here, ex-vivo approach 
and an in-vivo study with ICU patients. This should allow having a complete view on sequestration of 
drugs by tubing, other components of the ECMO-circuit as well as the effect of patient’s condition on 
drug pharmacokinetics. 
 
 
 
Legend: 
Figure1: Percentage of remaining concentration of cephalosporins and carbapenems according to 
time of incubation, (mean +/- standard deviation, n=5 ). No significant differences were observed 
between experimental and control conditions. (A) Imipenem: p= 0.38, (B) Meropenem: p= 0.50, (C) 
Ertapenem: p= 0.84, (D) Cefotaxime: p= 0.62, (E) Ceftriaxone: p= 0.09, (F) Ceftazidime: p= 0.35, (G) 
Cefepime: p= 0.27   
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